Region Midtjylland
Verified site
Aarhus, Denmark
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
CLN3 Disease is a rare inherited condition that begins in childhood and leads to progressive loss of vision, difficulties with movement, seizures, and changes in behavior and thinking. The study will use a medicine called Miglustat that is supplied as a flavored oral liquid (Batten‑1) taken by mouth each day.
The aim of the study is to find out whether daily treatment with this medicine can slow the worsening of the disease’s signs and symptoms during a one‑year period. Participants will receive the study drug for 52 weeks and will attend regular visits where simple tests will be done to check eyesight (using a chart that measures how clearly letters can be seen), walking ability, speech clarity, and overall health. Small blood samples will also be taken to look for substances that may indicate disease activity. The study does not involve any comparison with another treatment.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Aarhus, Denmark
Utrecht, The Netherlands
Gothenburg, Sweden
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.